Eschalier Romain, Souteyrand Géraud, Jean Frédéric, Roux Antoine, Combaret Nicolas, Saludas Yannick, Clerfond Guillaume, Barber-Chamoux Nicolas, Citron Bernard, Lusson Jean-René, Brugada Pedro, Motreff Pascal
Cardiology Department, Clermont-Ferrand University Hospital, 58, rue Montalembert, 63000 Clermont-Ferrand, France; Clermont université, université d'Auvergne, CArdio-Vascular Interventional Therapy and Imaging (CaVITI), Image Science for Interventional Techniques (ISIT), UMR6284, Clermont-Ferrand, France.
Cardiology Department, Clermont-Ferrand University Hospital, 58, rue Montalembert, 63000 Clermont-Ferrand, France; Clermont université, université d'Auvergne, CArdio-Vascular Interventional Therapy and Imaging (CaVITI), Image Science for Interventional Techniques (ISIT), UMR6284, Clermont-Ferrand, France.
Arch Cardiovasc Dis. 2014 Jan;107(1):42-7. doi: 10.1016/j.acvd.2013.10.006. Epub 2013 Dec 25.
Vasospastic angina is a frequent and well-recognized pathology with a high risk of life-threatening ventricular arrhythmias and sudden cardiac death. The diagnosis of vasospastic angina requires the combination of clinical and electrocardiographic variables and the results of provocation tests, such as ergonovine administration. Smoking cessation is the first step in the management of vasospastic angina. Optimal medical treatment using calcium-channel blockers and/or nitrate derivatives can provide protection, but life-threatening ventricular arrhythmias may occur despite optimal medical treatment and several years after the start of treatment. In this review, we evaluate the role of implantable defibrillators as a complement to optimal medical management in patients with life-threatening ventricular arrhythmias due to vasospastic angina; this role is not well characterized in the literature or guidelines. We discuss the role of implantable defibrillators in secondary prevention in light of three recent cases managed in our departments and a review of the literature. An implantable defibrillator was implanted in two of the three cases of vasospastic angina with ventricular arrhythmias that we managed. We considered secondary prevention by implantable defibrillator to be justified even in the absence of any obvious risk factor. Ventricular arrhythmias recurred during implantable defibrillator follow-up in the two patients implanted.
In patients with life-threatening ventricular arrhythmias due to vasospastic angina, an implantable defibrillator should be considered because of the risk of recurrence despite optimal medical management.
变异性心绞痛是一种常见且已被充分认识的病理状况,具有发生危及生命的室性心律失常和心源性猝死的高风险。变异性心绞痛的诊断需要结合临床和心电图变量以及激发试验(如麦角新碱给药)的结果。戒烟是变异性心绞痛管理的第一步。使用钙通道阻滞剂和/或硝酸酯类衍生物的最佳药物治疗可以提供保护,但尽管进行了最佳药物治疗且在治疗开始数年之后,仍可能发生危及生命的室性心律失常。在本综述中,我们评估植入式除颤器作为对因变异性心绞痛导致危及生命的室性心律失常患者的最佳药物治疗补充的作用;该作用在文献或指南中并未得到很好的描述。我们根据我们科室处理的三例近期病例以及文献综述,讨论植入式除颤器在二级预防中的作用。在我们处理的三例伴有室性心律失常的变异性心绞痛病例中,有两例植入了植入式除颤器。即使没有任何明显的危险因素,我们认为植入式除颤器进行二级预防也是合理的。在植入植入式除颤器的两名患者的随访期间,室性心律失常复发。
对于因变异性心绞痛导致危及生命的室性心律失常的患者,尽管进行了最佳药物治疗仍有复发风险,应考虑植入植入式除颤器。